AtheroGenics (NASDAQ: AGIX) September options active at higher prices into Data. AGIX closed up 41 cents to $2.49. AGIX focuses on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases. AGIX announced on 8/29/07 new scientific data of its oral antidiabetic agent AGI-1067 will be presented at the European Society of Cardiology Congress on 9/5/07 in Vienna, Austria. AGIX call option volume of 18,320 contracts compares to put volume of 13,171 contracts. AGIX at the money September 2.5 straddle is priced at 90 cents according to Track Data, suggesting larger price moment.
Volatility Index S&P 500 Options (OPR: VIX) up 1.25 to 25.06.
Daily options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.
Struggling Playboy outsources business ops
J. Crew earnings preview: A strong Q3 all buttoned up?
Twitter to make acquisitions, generate revenue in 2010
